IMV Inc. (NASDAQ:IMV) Q2 2019 Earnings Conference Call - Final Transcript

Aug 09, 2019 • 08:00 am ET


IMV Inc. (NASDAQ:IMV) Q2 2019 Earnings Conference Call - Final Transcript


Loading Event

Loading Transcript


Good morning, ladies and gentlemen, and welcome to the IMV Second Quarter 2019 Earnings and Operational Update Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will follow at that time. [Operator Instructions] As a reminder, this conference call is being recorded.

I would now like to turn the conference over to your host, Mr. Pierre Labbe, Chief Financial Officer.

Pierre Labbe

Thank you. Good morning, ladies and gentlemen. My name is Pierre Labbe, I'm CFO at IMV, and I'm happy to welcome you to our second quarter results results conference call. Joining me today for the formal portion of the call is Fred Ors, our President and CEO, and also Ms. Gabriela Rosu, Chief Medical Officer; and Ms. Marianne Stanford, VP, R&D will be available to answer questions. Fred will begin with his comment and I will then carry on with the financial highlight.

Before we begin, I would like to remind you that except for historical information, this presentation contains forward-looking statements, which reflects IMV current expectations regarding future events. These forward-looking statements involve known and unknown risks and uncertainties that could cause IMV's actual results to differ materially from those statements. Those risks and uncertainties include, but are not limited to, our ability to access capital, the successful and timely completion of clinical trials, the receipt of all regulatory approvals and other risks detailed from time to time in our ongoing quarterly filings and annual information form.

The forward-looking statements made on this call are based on several assumptions which may prove to be incorrect, and they represent views only as of the date of this call and are presented for the purpose of assisting potential investors in understanding IMV's business and may not be appropriate for other purposes. IMV does not undertake to update forward-looking statements whether written or oral, that may be made from time to time by or on its behalf, except as required under applicable securities legislation.

Investors are cautioned not to rely on these forward-looking statements and are encouraged to read IMV's continuous disclosure documents, including its current annual information form as well as its audited annual consolidated financial statements, which are available on SEDAR and on EDGAR. The press release, the MD&A, the consolidated financial statements and a copy of today's presentation are all posted in the IMV's website at If you wish to receive a copy of either of these documents, please do not hesitate to contact us.

Finally, take note that we will take questions only from sell-side financial analysts. Fred will now start with his comments. Fred?

Frederic Ors

Thank you, Pierre, and good morning, everybody. The DPX-Survivac program continues to be a major revenue driver for IMV with its unique mechanism of action providing significant industry differentiation and the potentially much-needed innovation for hard-to-treat cancers, both as monotherapy and in combination with other agents. Supporting these cases, in the second quarter, we reported important clinical updates on two Phase